{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-25-000066","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2025-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.223291+00:00","generated_at":"2026-05-23T21:07:13.447993+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arvinas Phase 1 data: ARV-102 achieves >50% central and >90% peripheral LRRK2 degradation","bullets":["ARV-102 well tolerated in healthy volunteers; no serious adverse events in SAD (completed) or MAD (ongoing) cohorts.","At single dose ≥60 mg and repeated ≥20 mg: >90% LRRK2 reduction in PBMCs and >50% in CSF.","Median Tmax 6h, terminal half-life 73h; CSF exposure dose-dependent across SAD and MAD.","Phase 1 trial in Parkinson's disease patients initiated Q4 2024; initial patient data expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-25-000066","json":"https://secwatch.observer/filing/0001655759-25-000066.json","markdown":"https://secwatch.observer/filing/0001655759-25-000066.md","text":"https://secwatch.observer/filing/0001655759-25-000066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575925000066/0001655759-25-000066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575925000066/arvn-20250404.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T21:07:13.447993+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}